However, FTIs were ineffective with regard to pancreatic cancers in phase II and III clinical trials in which oncogenic mutant K-Ras was found in 88% of all pancreatic cancers (Cohen et al., 2003; Van Cutsem et al., 2004; Macdonald et al., 2005). Here, KRAS is linked to familial pancreatic carcinoma.